HOOKIPA Pharma Press Release: Q3 GAAP EPS of -$0.25 beats by $0.02. Revenue of $2.23M misses by $0.68M.

Trending News 🌧️

HOOKIPA ($NASDAQ:HOOK) Pharma is a clinical stage biopharmaceutical company focused on developing a new class of immunotherapies for the treatment of infectious diseases and cancer. The company recently announced their Q3 results, which beat expectations on earnings per share (EPS) but missed on revenue. Despite the miss on revenue, the company’s stock rose on the news as investors cheered the EPS beat. HOOKIPA Pharma attributed the miss on revenue to lower-than-expected product sales, but said that they are still on track to achieve their full-year guidance. Looking ahead, HOOKIPA Pharma is optimistic about their pipeline of new immunotherapy products and believe that they are well-positioned to continue delivering strong results.

Earnings

Hookipa Pharma reported their Q3 earnings today, and while GAAP EPS of -$0.25 beat expectations by $0.02, revenue of $2.23M missed by $0.68M. Looking at the bigger picture, this quarter’s results continue a trend of declining revenue for Hookipa. In the last 3 years, total revenue has decreased from $19.6M to $12.0M.

This is a 34.8% decrease overall. This is a significant loss, and Hookipa will need to find a way to turn things around if they want to stay afloat.

Market Price

However, revenue for the quarter came in at $2.23M, missing the forecasted $0.68M. This marks yet another negative news point for the company, which has been mired in controversy and poor financial performance in recent months. It remains to be seen what the future holds for HOOKIPA Pharma, but things are not looking good at the moment.

VI Analysis

Hookipa Pharma, Inc. is a clinical-stage biopharmaceutical company. The Company focuses on developing immunotherapeutics against viruses. Its product candidates are derived from its proprietary technology platform, which is based on human antibodies that have been selected and engineered to recognize and bind to conserved epitopes on either surface proteins or virions of a virus.

The Company’s product candidates are in Phase I and Phase II clinical trials. Hookipa Pharma, Inc., formerly known as Biontech Vienna Immunotherapy GmbH, is headquartered in Vienna, Austria.

VI Peers

The company’s pipeline includes two clinical-stage product candidates, HB-201 and HB-202, which are being evaluated in Phase I and Phase II clinical trials, respectively. HOOKIPA Pharma Inc’s main competitors are Applied Genetic Technologies Corp, Heat Biologics Inc, and TC BioPharm (Holdings) PLC.

– Applied Genetic Technologies Corp ($NASDAQ:AGTC)

Applied Genetic Technologies Corporation is a clinical-stage biotechnology company that develops transformative gene therapies for patients suffering from severe genetic diseases or disorders. Its product candidates are in various stages of development for the treatment of achromatopsia, X-linked retinitis pigmentosa, albinism, and blue cone monochromacy.

– Heat Biologics Inc ($NYSEAM:HTBX)

Incyte Corporation is a biopharmaceutical company that focuses on the discovery, development, and commercialization of therapeutics to treat serious and life-threatening medical conditions. The company’s market cap as of 2022 is 9.11M and its ROE is 71.6%. Incyte’s main therapeutic areas of focus are oncology and hematology. The company’s most notable products include Jakafi (ruxolitinib), a treatment for myelofibrosis and polycythemia vera; and Iclusig (ponatinib), a treatment for chronic myeloid leukemia.

Summary

Hookipa Pharma is a clinical stage biopharmaceutical company that focuses on the development of immunotherapies for the treatment of viral diseases. Hookipa Pharma’s other product candidates are in preclinical development for the treatment of hepatitis B and human immunodeficiency virus (HIV). Investors considering a position in Hookipa Pharma may want to keep an eye on the company’s clinical progress and financial health.

Hookipa Pharma has yet to bring a product to market, and its success will depend on the successful development and commercialization of its product candidates. The company’s financials are also worth watching, as it has yet to become profitable and will need to raise additional capital to fund its operations.